Related Experiment Videos
Evaluation of circulating calcitonin: analytical aspects
Antonia Martinetti1, Ettore Seregni, Leonardo Ferrari
1Nuclear Medicine Division, National Cancer Institute, Milan, Italy.
Tumori
|February 12, 2004
Summary
Different assays for measuring serum calcitonin (hCT) yield widely dispersed results, impacting medullary thyroid carcinoma diagnosis. Patient classification depends heavily on the specific assay used, highlighting analytical inaccuracies.
Area of Science:
- Endocrinology
- Oncology
- Clinical Chemistry
Background:
- Serum calcitonin (hCT) is a key biomarker for medullary thyroid carcinoma (MTC) diagnosis and monitoring.
- Discrepancies between different assay methods complicate hCT result interpretation.
Purpose of the Study:
- To compare the performance of four commercially available immunoradiometric (IRMA) and radioimmunometric (RIA) assays for hCT determination.
- To assess the impact of assay variability on patient classification for MTC.
Main Methods:
- Serum hCT levels were measured in 35 MTC patients using four distinct IRMA/RIA kits.
- Statistical analysis included comparison of hCT value distribution and correlation analysis between assays.
Main Results:
- Significant dispersion of hCT values was observed across the tested assays.
- Patient classification based on hCT cutoff values varied considerably depending on the assay employed.
Conclusions:
- Analytical inaccuracy remains a significant challenge in hCT evaluation, despite advancements in antibody development.
- Assay-dependent variability in hCT measurements necessitates careful consideration of the specific method used for clinical decision-making in MTC.